Cyclosporine 0.1% (Ikervis(®)) as a corticoid-sparing agent in Lyell syndrome with KeraKlear(®) keratoprosthesis

Cyclosporine 0.1% was used in a patient with Lyell syndrome, which had undergone a KeraKlear(®) keratoprosthesis implant due to the severe ocular involvement to avoid overuse of corticoid agents. To the best of our knowledge, this is the first reported case of cyclosporine 0.1% eye drops to use in L...

Descripción completa

Detalles Bibliográficos
Autores principales: Rahhal-Ortuño, Miriam, Fernández-Santodomingo, Alex-Samir, Villena-Alvarado, Carla, Marín-Payá, Emma, Aguilar-González, Marina, García-Delpech, Salvador
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer - Medknow 2020
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7787086/
https://www.ncbi.nlm.nih.gov/pubmed/33437608
http://dx.doi.org/10.4103/tjo.tjo_1_20
Descripción
Sumario:Cyclosporine 0.1% was used in a patient with Lyell syndrome, which had undergone a KeraKlear(®) keratoprosthesis implant due to the severe ocular involvement to avoid overuse of corticoid agents. To the best of our knowledge, this is the first reported case of cyclosporine 0.1% eye drops to use in Lyell syndrome previously treated with keratoprosthesis implant.

Ejemplares similares